View More View Less
  • 1 University of Szeged Department of Biotechnology Szeged Hungary
  • | 2 Enviroinvest Corporation Department of Biotechnology Pécs Hungary
  • | 3 University of Pécs Institute of Medical Microbiology and Immunology Pécs Hungary
  • | 4 Hungarian Academy of Sciences Institute of Biophysics, Biological Research Center Szeged Hungary
Restricted access

Purchase article

USD  $25.00

1 year subscription (Individual Only)

USD  $784.00

The emergence of the multi-drug-resistant Staphylococcus aureus strains has prompted interest in alternatives to conventional drugs. Among the possible options one of the most promising is the therapeutic use of bacteriophages. Over the recent decades, increasing amount of literature has validated the use of bacteriophages for therapy and prophylaxis against drug-resistant staphylococci. This work attempts to review the current knowledge on bacteriophages and their usages for treatment of staphylococcal diseases.

  • Watkins, R.R., David, M.Z., Salata, R.A.: Current concepts on the virulence mechanisms of meticillin-resistant Staphylococcus aureus. J Med Microbiol 61, 1179–1193 (2012).

    Salata R.A. , 'Current concepts on the virulence mechanisms of meticillin-resistant Staphylococcus aureus ' (2012 ) 61 J Med Microbiol : 1179 -1193.

    • Search Google Scholar
  • van Hal, S.J., Jensen, S.O., Vaska, V.L., Espedido, B.A., Paterson, D.L., Gosbell, I.B.: Predictors of mortality in Staphylococcus aureus Bacteremia. ClinMicrobiol Rev 25, 362–386 (2012).

    Gosbell I.B. , 'Predictors of mortality in Staphylococcus aureus Bacteremia ' (2012 ) 25 ClinMicrobiol Rev : 362 -386.

    • Search Google Scholar
  • Rajan, S.: Skin and soft-tissue infections: Classifying and treating a spectrum. Cleve Clin J Med 79, 57–66 (2012).

    Rajan S. , 'Skin and soft-tissue infections: Classifying and treating a spectrum ' (2012 ) 79 Cleve Clin J Med : 57 -66.

    • Search Google Scholar
  • Dryden, M.S.: Complicated skin and soft tissue infection. J Antimicrob Chemother 65, iii35–44 (2010).

    Dryden M.S. , 'Complicated skin and soft tissue infection ' (2010 ) 65 J Antimicrob Chemother : iii35 -44.

    • Search Google Scholar
  • Crum-Cianflone, N.F.: Bacterial, fungal, parasitic, and viral myositis. Clin Microbiol Rev 21, 473–494 (2008).

    Crum-Cianflone N.F. , 'Bacterial, fungal, parasitic, and viral myositis ' (2008 ) 21 Clin Microbiol Rev : 473 -494.

    • Search Google Scholar
  • Uluð, M., Ayaz, C., Celen, M.K.: A case report and literature review: osteomyelitis caused by community-associated methicillin resistant Staphylococcus aureus. J Infect Dev Count 5, 896–900 (2011).

    Celen M.K. , 'A case report and literature review: osteomyelitis caused by community-associated methicillin resistant Staphylococcus aureus ' (2011 ) 5 J Infect Dev Count : 896 -900.

    • Search Google Scholar
  • Boucher, H., Miller, L.G., Razonable, R.R.: Serious infections caused by methicillin-resistant Staphylococcus aureus. Clin Infect Dis 51, S183–197 (2010).

    Razonable R.R. , 'Serious infections caused by methicillin-resistant Staphylococcus aureus ' (2010 ) 51 Clin Infect Dis : S183 -197.

    • Search Google Scholar
  • Shirtliff, M.E., Mader, J.T.: Acute septic arthritis. Clin Microbiol Rev 15, 527–544 (2002).

    Mader J.T. , 'Acute septic arthritis ' (2002 ) 15 Clin Microbiol Rev : 527 -544.

  • Pletz, M.W., Burkhardt, O., Welte, T.: Nosocomial methicillin-resistant Staphylococcus aureus (MRSA) pneumonia: Linezolid or vancomycin? — Comparison of pharmacology and clinical efficacy. Eur J Med Res 15, 507–513 (2010).

    Welte T. , 'Nosocomial methicillin-resistant Staphylococcus aureus (MRSA) pneumonia: Linezolid or vancomycin? — Comparison of pharmacology and clinical efficacy ' (2010 ) 15 Eur J Med Res : 507 -513.

    • Search Google Scholar
  • Montanaro, L., Speziale, P., Campoccia, D., Ravaioli, S., Cangini, I., Pietrocola, G., Giannini, S., Arciola, C.R.: Scenery of Staphylococcus implant infections in orthopedics. Future Microbiol. 6, 1329–1349 (2011).

    Arciola C.R. , 'Scenery of Staphylococcus implant infections in orthopedics ' (2011 ) 6 Future Microbiol. : 1329 -1349.

    • Search Google Scholar
  • Chambers, S.T.: Diagnosis and management of staphylococcal infections of pacemakers and cardiac defibrillators. Internal Med J 35, S63–71 (2005).

    Chambers S.T. , 'Diagnosis and management of staphylococcal infections of pacemakers and cardiac defibrillators ' (2005 ) 35 Internal Med J : S63 -71.

    • Search Google Scholar
  • Hadaway, L.: Short peripheral intravenous catheters and infections. J Infus Nursing 35, 230–240 (2012).

    Hadaway L. , 'Short peripheral intravenous catheters and infections ' (2012 ) 35 J Infus Nursing : 230 -240.

    • Search Google Scholar
  • Shah, S.S., Smith, M.J., Zaoutis, T.E.: Device-related infections in children. Pediatr Clin North Am 52, 1189–1208 (2005).

    Zaoutis T.E. , 'Device-related infections in children ' (2005 ) 52 Pediatr Clin North Am : 1189 -1208.

    • Search Google Scholar
  • Ortega, E., Abriouel, H., Lucas, R., Gálvez, A.: Multiple roles of Staphylococcus aureus enterotoxins: Pathogenicity, superantigenic activity, and correlation to antibiotic resistance. Toxins 2, 2117–2131 (2010).

    Gálvez A. , 'Multiple roles of Staphylococcus aureus enterotoxins: Pathogenicity, superantigenic activity, and correlation to antibiotic resistance ' (2010 ) 2 Toxins : 2117 -2131.

    • Search Google Scholar
  • Pinchuk, I.V., Beswick, E.J., Reyes, V.E.: Staphylococcal enterotoxins. Toxins 2, 2177–2197 (2010).

    Reyes V.E. , 'Staphylococcal enterotoxins ' (2010 ) 2 Toxins : 2177 -2197.

  • Dulon, M., Haamann, F., Peters, C., Schablon, A., Nienhaus, A.: MRSAprevalence in Euro-pean healthcare settings: A review. BMC Infect Dis 11, 138 (2011).

    Nienhaus A. , 'MRSAprevalence in Euro-pean healthcare settings: A review ' (2011 ) 11 BMC Infect Dis : 138 -.

    • Search Google Scholar
  • Barber, M.: Methicillin-resistant staphylococci. J Clin Pathol 14, 385–393 (1961).

    Barber M. , 'Methicillin-resistant staphylococci ' (1961 ) 14 J Clin Pathol : 385 -393.

  • Arias, C.A., Murray, B.E.: Antibiotic-resistant bugs in the 21st century — A clinical super-challenge. N Engl J of Med 360, 439–443 (2009).

    Arias C.A. , 'Murray, B.E.: Antibiotic-resistant bugs in the 21st century — A clinical super-challenge ' (2009 ) 360 N Engl J of Med : 439 -443.

    • Search Google Scholar
  • Burkhardt, O., Pletz, M.W., Mertgen, C.-P., Welte, T.: Linezolid — The first oxazolidinone in the treatment of nosocomial MRSA pneumonia. Recent Pat Anti-infect Drug Disc 2, 23–30 (2007).

    Welte T. , 'Linezolid — The first oxazolidinone in the treatment of nosocomial MRSA pneumonia ' (2007 ) 2 Recent Pat Anti-infect Drug Disc : 23 -30.

    • Search Google Scholar
  • Baudoux, P., Lemaire, S., Denis, O., Tulkens, P.M., van Bambeke, F., Glupczynski, Y.: Activity of quinupristin/dalfopristin against extracellular and intracellular Staphylococcus aureuswith various resistance phenotypes. J Antimicrob Chemother 65, 1228–1236 (2010).

    Glupczynski Y. , 'Activity of quinupristin/dalfopristin against extracellular and intracellular Staphylococcus aureuswith various resistance phenotypes ' (2010 ) 65 J Antimicrob Chemother : 1228 -1236.

    • Search Google Scholar
  • Bhavnani, S.M., Rubino, C.M., Hammel, J.P., Forrest, A., Dartois, N., Cooper, C.A., Korth-Bradley, J., Ambrose, P.G.: Pharmacological and patient-specific response determinants in patients with hospital-acquired pneumonia treated with tigecycline. Antimicrob Agents Chemother 56, 1065–1072 (2012).

    Ambrose P.G. , 'Pharmacological and patient-specific response determinants in patients with hospital-acquired pneumonia treated with tigecycline ' (2012 ) 56 Antimicrob Agents Chemother : 1065 -1072.

    • Search Google Scholar
  • Liu, Y., Cui, J., Wang, R., Wang, X., Drlica, K., Zhao, X.: Selection of rifampicin-resistant Staphylococcus aureus during tuberculosis therapy: concurrent bacterial eradication and acquisition of resistance. J Antimicrob Chemother 56, 1172–1175 (2005).

    Zhao X. , 'Selection of rifampicin-resistant Staphylococcus aureus during tuberculosis therapy: concurrent bacterial eradication and acquisition of resistance ' (2005 ) 56 J Antimicrob Chemother : 1172 -1175.

    • Search Google Scholar
  • Howden, B.P., Grayson, M.L.: Dumb and dumber — The potential waste of a useful antistaphylococcal agent: Emerging fusidic acid resistance in Staphylococcus aureus. Clin Infect Dis 42, 394–400 (2006).

    Grayson M.L. , 'Dumb and dumber — The potential waste of a useful antistaphylococcal agent: Emerging fusidic acid resistance in Staphylococcus aureus ' (2006 ) 42 Clin Infect Dis : 394 -400.

    • Search Google Scholar
  • Kurlenda, J., Grinholc, M.: Alternative therapies in Staphylococcus aureus diseases. Acta Biochim Pol 59, 171–184 (2012).

    Grinholc M. , 'Alternative therapies in Staphylococcus aureus diseases ' (2012 ) 59 Acta Biochim Pol : 171 -184.

    • Search Google Scholar
  • Twort, F.W.: An investigation on the nature of ultra-microscopic viruses. Lancet 186, 1241–1243 (1915).

    Twort F.W. , 'An investigation on the nature of ultra-microscopic viruses ' (1915 ) 186 Lancet : 1241 -1243.

    • Search Google Scholar
  • Bruynoghe, R., Maisin, J.: Essais de thérapeutique au moyen du bacteriophage. Comptes Rendus des Séances et Mémoires de la Société de Biologie 85, 1120–1121 (1921).

    Maisin J. , 'Essais de thérapeutique au moyen du bacteriophage ' (1921 ) 85 Comptes Rendus des Séances et Mémoires de la Société de Biologie : 1120 -1121.

    • Search Google Scholar
  • Straub, M.E., Applebaum, M.B.A.: Studies on commercial bacteriophage products. JAMA 100, 110 (1933).

    Applebaum M.B.A. , 'Studies on commercial bacteriophage products ' (1933 ) 100 JAMA : 110 -.

  • Chanishvili, N.: Phage therapy — History from Twort and ďHerelle through Soviet experi-ence to current approaches. Adv Virus Res 83, (2012).

  • Villa, T.G., Veiga-Crespo, P.: Advantages and disadvantages in the use of antibiotics or phages as therapeutic agents. In: Enzybiotics: Antibiotic Enzyme, and Therapeutics. Eds Villa, T.G., Veiga-Crespo, P. JohnWiley & Sons, Inc. ISBN 978-0-470-37655-3, 2010, pp. 27–58.

    Veiga-Crespo P. , '', in Enzybiotics: Antibiotic Enzyme, and Therapeutics , (2010 ) -.

  • Sulakvelidze, A., Kutter, E.: Bacteriophage therapy in humans. In: Bacteriophages: Biology and Applications. Eds Kutter, E., Sulakvelidze, A. Boca Raton, FL: CRC Press, 2005, pp. 377–428.

    Kutter E. , '', in Bacteriophages: Biology and Applications , (2005 ) -.

  • Burman, L.G., Lundblad, G., Cammer, P., Fange, R., Lundborg, M., Soder, P.: Lysozyme — An enzyme of both historical and current interest as a therapeutical agent. Lakartidningen 88, 3665–3668 (1991).

    Soder P. , 'Lysozyme — An enzyme of both historical and current interest as a therapeutical agent ' (1991 ) 88 Lakartidningen : 3665 -3668.

    • Search Google Scholar
  • Shearman, C.A., Jury, K.L., Gasson, M.J.: Controlled expression and structural organization of a Lactococcus lactis bacteriophage lysin encoded by two overlapping genes. Appl and Environ Microbiol 60, 3063–3073 (1994).

    Gasson M.J. , 'Controlled expression and structural organization of a Lactococcus lactis bacteriophage lysin encoded by two overlapping genes ' (1994 ) 60 Appl and Environ Microbiol : 3063 -3073.

    • Search Google Scholar
  • Ibrahim, H.R., Aoki, T., Pellegrini, A.: Strategies for new antimicrobial proteins and peptides: Lysozyme and aprotinin as model molecules. Curr Pharm Des 8, 671–693 (2002).

    Pellegrini A. , 'Strategies for new antimicrobial proteins and peptides: Lysozyme and aprotinin as model molecules ' (2002 ) 8 Curr Pharm Des : 671 -693.

    • Search Google Scholar
  • Touch, V.S., Hayakawa, K., Fukada, Y., Aratani, Sun, Y.: Preparation of antimicrobial reduced lysozyme compatible in food applications. J Agric Food Chem 51, 5154–5161 (2003).

    Aratani S. Y. , 'Preparation of antimicrobial reduced lysozyme compatible in food applications ' (2003 ) 51 J Agric Food Chem : 5154 -5161.

    • Search Google Scholar
  • Delfini, C., Cersosimo, M., Del Prete, V., Strano, M., Gaetano, G., Pagliara, A., Ambrò, S.: Resistance screening essay of wine lactic acid bacteria on lysozyme: Efficacy of lysozyme in unclarified grape musts. J Agric Food Chem 52, 1861–1866 (2004).

    Ambrò S. , 'Resistance screening essay of wine lactic acid bacteria on lysozyme: Efficacy of lysozyme in unclarified grape musts ' (2004 ) 52 J Agric Food Chem : 1861 -1866.

    • Search Google Scholar
  • Hermoso, J.A., Garcia, J.L., Garcia, P.: Taking aimon bacterial pathogens: fromphage therapy to enzybiotics. Curr Opin Microbiol 10, 461–472 (2007).

    Garcia P. , 'Taking aimon bacterial pathogens: fromphage therapy to enzybiotics ' (2007 ) 10 Curr Opin Microbiol : 461 -472.

    • Search Google Scholar
  • Nau, R., Eiffert, H.: Modulation of release of proinflammatory bacterial compounds by antibacterials: Potential impact on course of inflammation and outcome in sepsis and meningitis. Clin Microbiol Rev 15, 95–110 (2002).

    Eiffert H. , 'Modulation of release of proinflammatory bacterial compounds by antibacterials: Potential impact on course of inflammation and outcome in sepsis and meningitis ' (2002 ) 15 Clin Microbiol Rev : 95 -110.

    • Search Google Scholar
  • Wentworth, B.B.: Bacteriophage typing of the Staphylococci. Bacteriol Rev 27, 253–272 (1963).

    Wentworth B.B. , 'Bacteriophage typing of the Staphylococci ' (1963 ) 27 Bacteriol Rev : 253 -272.

    • Search Google Scholar
  • Kwan, T., Liu, J., DuBow, M., Gros, P., Pelletier, J.: The complete genomes and proteomes of 27 Staphylococcus aureus bacteriophages. Proc Natl Acad Sci USA 102, 5174–5179 (2005).

    Pelletier J. , 'The complete genomes and proteomes of 27 Staphylococcus aureus bacteriophages ' (2005 ) 102 Proc Natl Acad Sci USA : 5174 -5179.

    • Search Google Scholar
  • Belcaid, M., Bergeron, A., Poisson, G.: Mosaic graphs and comparative genomics in phage communities. J Comput Biol 17, 1315–1326 (2010) doi: 10.1089/cmb.2010.0108

    Poisson G. , 'Mosaic graphs and comparative genomics in phage communities ' (2010 ) 17 J Comput Biol : 1315 -1326.

    • Search Google Scholar
  • Łobocka, M., Hejnowicz, M.S., Dąbrowski, K., Gozdek, A., Kosakowski, J., Witkowska, M., Ulatowska, M.I., Weber-Dąbrowska, B., Kwiatek, M., Parasion, S., Gawor, J., Kosowska, H., Glowacka, A.: Genomics of staphylococcal Twort-like phages — Potential therapeutics of the post-antibiotic era. Adv Virus Res 83, 143–216 (2012).

    Glowacka A. , 'Genomics of staphylococcal Twort-like phages — Potential therapeutics of the post-antibiotic era ' (2012 ) 83 Adv Virus Res : 143 -216.

    • Search Google Scholar
  • O’Flaherty, S., Ross, R.P., Flynn, J., Meaney, W.J., Fitzgerald, G.F., Coffey, A.: Isolation and characterization of two anti-staphylococcal bacteriophages specific for pathogenic Staphylococcus aureus associated with bovine infections. Lett ApplMicrobiol 41, 482–486 (2005).

    Coffey A. , 'Isolation and characterization of two anti-staphylococcal bacteriophages specific for pathogenic Staphylococcus aureus associated with bovine infections ' (2005 ) 41 Lett ApplMicrobiol : 482 -486.

    • Search Google Scholar
  • Matsuzaki, S., Yasuda, M., Nishikawa, H., Kuroda, M., Ujihara, T., Shuin, T., Shen, Y., Jin, Z., Fujimoto, S., Nasimuzzaman, M.D., Wakiguchi, H., Sugihara, S., Sugiura, T., Koda, S., Muraoka, A., Imai, S.: Experimental protection of mice against lethal Staphylococcus aureus infection by novel bacteriophage phi MR11. J Infect Dis 187, 613–624 (2003).

    Imai S. , 'Experimental protection of mice against lethal Staphylococcus aureus infection by novel bacteriophage phi MR11 ' (2003 ) 187 J Infect Dis : 613 -624.

    • Search Google Scholar
  • Capparelli, R., Parlato, M., Borriello, G., Salvatore, P., Iannelli, D.: Experimental phage therapy against Staphylococcus aureus in mice. Antimicrob Agents Chemother 51, 2765–2773 (2007).

    Iannelli D. , 'Experimental phage therapy against Staphylococcus aureus in mice ' (2007 ) 51 Antimicrob Agents Chemother : 2765 -2773.

    • Search Google Scholar
  • “Eliava Institute.” [Online]. Available: http://www.eliava-institute.org/

  • Duckworth, D.H., Gulig, P.A.: Bacteriophages: potential treatment for bacterial infections. BioDrugs 16, 57–62 (2002).

    Gulig P.A. , 'Bacteriophages: potential treatment for bacterial infections ' (2002 ) 16 BioDrugs : 57 -62.

    • Search Google Scholar
  • Brüssow, H.: What is needed for phage therapy to become a reality in Western medicine? Virology 434, 138–142 (2012).

    Brüssow H. , 'What is needed for phage therapy to become a reality in Western medicine ' (2012 ) 434 Virology : 138 -142.

    • Search Google Scholar
  • Merabishvili, M., Pirnay, J.-P., Verbeken, G., Chanishvili, N., Tediashvili, M., Lashkhi, N., Glonti, T., Krylov, V., Mast, J., Van Parys, L., Lavigne, R., Volckaert, G., Mattheus, W., Verween, G., De Corte, P., Rose, T., Jennes, S., Zizi, M., De Vos, D., Vaneechoutte, M.: Quality-controlled small-scale production of a well-defined bacteriophage cocktail for use in human clinical trials. PloS One 4, e4944 (2009).

    Vaneechoutte M. , 'Quality-controlled small-scale production of a well-defined bacteriophage cocktail for use in human clinical trials ' (2009 ) 4 PloS One : e4944 -.

    • Search Google Scholar
  • Verbeken, G., Pirnay, J.-P., De Vos, D., Jennes, S., Zizi, M., Lavigne, R., Casteels, M., Huys, I.: Optimizing the European regulatory framework for sustainable bacteriophage therapy in human medicine. Arch Immunol Ther Exp 60, 161–172 (2012).

    Huys I. , 'Optimizing the European regulatory framework for sustainable bacteriophage therapy in human medicine ' (2012 ) 60 Arch Immunol Ther Exp : 161 -172.

    • Search Google Scholar
  • Thiel, K.: Old dogma, new tricks — 21st century phage therapy. Nat Biotechnol 22, 31–36 (2004).

    Thiel K. , 'Old dogma, new tricks — 21st century phage therapy ' (2004 ) 22 Nat Biotechnol : 31 -36.

    • Search Google Scholar

 

The author instruction is available in PDF.
Please, download the file from HERE

Senior editors

Editor-in-Chief: Prof. Dóra Szabó (Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary)

Managing Editor: Dr. Béla Kocsis (Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary)

Co-editor: Dr. Andrea Horváth (Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary)

Editorial Board

  • Prof. Éva ÁDÁM (Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary)
  • Prof. Sebastian AMYES (Department of Medical Microbiology, University of Edinburgh, Edinburgh, UK.)
  • Dr. Katalin BURIÁN (Institute of Clinical Microbiology University of Szeged, Szeged, Hungary; Department of Medical Microbiology and Immunobiology, University of Szeged, Szeged, Hungary.)
  • Dr. Orsolya DOBAY (Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary)
  • Prof. Ildikó Rita DUNAY (Institute of Inflammation and Neurodegeneration, Medical Faculty, Otto-von-Guericke University, Magdeburg, Germany; Center for Behavioral Brain Sciences (CBBS), Magdeburg, Germany)
  • Prof. Levente EMŐDY(Department of Medical Microbiology and Immunology, University of Pécs, Pécs, Hungary.)
  • Prof. Anna ERDEI (Department of Immunology, Eötvös Loránd University, Budapest, Hungary, MTA-ELTE Immunology Research Group, Eötvös Loránd University, Budapest, Hungary.)
  • Prof. Éva Mária FENYŐ (Division of Medical Microbiology, University of Lund, Lund, Sweden)
  • Prof. László FODOR (Department of Microbiology and Infectious Diseases, University of Veterinary Medicine, Budapest, Hungary)
  • Prof. József KÓNYA (Department of Medical Microbiology, University of Debrecen, Debrecen, Hungary)
  • Prof. Yvette MÁNDI (Department of Medical Microbiology and Immunobiology, University of Szeged, Szeged, Hungary)
  • Prof. Károly MÁRIALIGETI (Department of Microbiology, Eötvös Loránd University, Budapest, Hungary)
  • Prof. János MINÁROVITS (Department of Oral Biology and Experimental Dental Research, University of Szeged, Szeged, Hungary)
  • Prof. Béla NAGY (Centre for Agricultural Research, Institute for Veterinary Medical Research, Budapest, Hungary.)
  • Prof. István NÁSZ (Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary)
  • Prof. Kristóf NÉKÁM (Hospital of the Hospitaller Brothers in Buda, Budapest, Hungary.)
  • Dr. Eszter OSTORHÁZI (Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary)
  • Prof. Rozália PUSZTAI (Department of Medical Microbiology and Immunobiology, University of Szeged, Szeged, Hungary)
  • Prof. Peter L. RÁDY (Department of Dermatology, University of Texas, Houston, Texas, USA)
  • Prof. Éva RAJNAVÖLGYI (Department of Immunology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary)
  • Prof. Ferenc ROZGONYI (Institute of Laboratory Medicine, Semmelweis University, Budapest, Hungary)
  • Prof. Zsuzsanna SCHAFF (2nd Department of Pathology, Semmelweis University, Budapest, Hungary)
  • Prof. Joseph G. SINKOVICS (The Cancer Institute, St. Joseph’s Hospital, Tampa, Florida, USA)
  • Prof. Júlia SZEKERES (Department of Medical Biology, University of Pécs, Pécs, Hungary.)
  • Prof. Mária TAKÁCS (National Reference Laboratory for Viral Zoonoses, National Public Health Center, Budapest, Hungary.)
  • Prof. Edit URBÁN (Department of Medical Microbiology and Immunology University of Pécs, Pécs, Hungary; Institute of Translational Medicine, University of Pécs, Pécs, Hungary.)

 

Editorial Office:
Akadémiai Kiadó Zrt.
Budafoki út 187-187, A/3, H-1117 Budapest, Hungary

Editorial Correspondence:
Acta Microbiologica et Immunologica Hungarica
Institute of Medical Microbiology
Semmelweis University
P.O. Box 370
H-1445 Budapest, Hungary
Phone: + 36 1 459 1500 ext. 56101
Fax: (36 1) 210 2959
E-mail: amih@med.semmelweis-univ.hu

 Indexing and Abstracting Services:

  • Biological Abstracts
  • BIOSIS Previews
  • CAB Abstracts
  • Chemical Abstracts
  • Global Health
  • Index Medicus
  • Index Veterinarius
  • Medline
  • Referativnyi Zhurnal
  • SCOPUS
  • Science Citation Index Expanded
2020  
Total Cites 662
WoS
Journal
Impact Factor
2,048
Rank by Immunology 145/162(Q4)
Impact Factor Microbiology 118/137 (Q4)
Impact Factor 1,904
without
Journal Self Cites
5 Year 0,671
Impact Factor
Journal  0,38
Citation Indicator  
Rank by Journal  Immunology 146/174 (Q4)
Citation Indicator  Microbiology 120/142 (Q4)
Citable 42
Items
Total 40
Articles
Total 2
Reviews
Scimago 28
H-index
Scimago 0,439
Journal Rank
Scimago Immunology and Microbiology (miscellaneous) Q4
Quartile Score Medicine (miscellaneous) Q3
Scopus 438/167=2,6
Scite Score  
Scopus General Immunology and Microbiology 31/45 (Q3)
Scite Score Rank  
Scopus 0,760
SNIP
Days from  225
sumbission
to acceptance
Days from  118
acceptance
to publication
Acceptance 19%
Rate

2019  
Total Cites
WoS
485
Impact Factor 1,086
Impact Factor
without
Journal Self Cites
0,864
5 Year
Impact Factor
1,233
Immediacy
Index
0,286
Citable
Items
42
Total
Articles
40
Total
Reviews
2
Cited
Half-Life
5,8
Citing
Half-Life
7,7
Eigenfactor
Score
0,00059
Article Influence
Score
0,246
% Articles
in
Citable Items
95,24
Normalized
Eigenfactor
0,07317
Average
IF
Percentile
7,690
Scimago
H-index
27
Scimago
Journal Rank
0,352
Scopus
Scite Score
320/161=2
Scopus
Scite Score Rank
General Immunology and Microbiology 35/45 (Q4)
Scopus
SNIP
0,492
Acceptance
Rate
16%

 

Acta Microbiologica et Immunologica Hungarica
Publication Model Online only Hybrid
Submission Fee none
Article Processing Charge 1100 EUR/article
Regional discounts on country of the funding agency World Bank Lower-middle-income economies: 50%
World Bank Low-income economies: 100%
Further Discounts Editorial Board / Advisory Board members: 50%
Corresponding authors, affiliated to an EISZ member institution subscribing to the journal package of Akadémiai Kiadó: 100%
Subscription fee 2021 Online subsscription: 652 EUR / 812 USD
Subscription fee 2022 Online subsscription: 662 EUR / 832 USD
Print + online subscription: 740 EUR / 930 USD
Subscription Information Online subscribers are entitled access to all back issues published by Akadémiai Kiadó for each title for the duration of the subscription, as well as Online First content for the subscribed content.
Purchase per Title Individual articles are sold on the displayed price.

Acta Microbiologica et Immunologica Hungarica
Language English
Size A4
Year of
Foundation
1954
Publication
Programme
2021 Volume 68
Volumes
per Year
1
Issues
per Year
4
Founder Magyar Tudományos Akadémia
Founder's
Address
H-1051 Budapest, Hungary, Széchenyi István tér 9.
Publisher Akadémiai Kiadó
Publisher's
Address
H-1117 Budapest, Hungary 1516 Budapest, PO Box 245.
Responsible
Publisher
Chief Executive Officer, Akadémiai Kiadó
ISSN 1217-8950 (Print)
ISSN 1588-2640 (Online)

Monthly Content Usage

Abstract Views Full Text Views PDF Downloads
Apr 2021 21 1 1
May 2021 4 0 0
Jun 2021 13 0 0
Jul 2021 17 0 0
Aug 2021 8 0 0
Sep 2021 1 0 0
Oct 2021 0 0 0